Stay updated on Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Sign up to get notified when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.

Latest updates to the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.5%
- Check17 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check24 days agoChange DetectedThe page has updated the number of study locations from 189 to 187 and has added new dates for the study, including 2025-05-29 and 2025-09-17. Additionally, the location details for Vinnytsia have been modified.SummaryDifference4%
- Check32 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check39 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
Stay in the know with updates to Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.